BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 14696456)

  • 1. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
    Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
    Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.
    Serejo F; Costa A; Oliveira AG; Ramalho F; Batista A; De Moura MC
    Dig Dis Sci; 2001 Aug; 46(8):1684-9. PubMed ID: 11508668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
    Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
    J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and response to interferon-alpha therapy.
    Giustina G; Fattovich G; De Paoli M; Guido M; Favarato S; Rugge M; Alberti A; Ruol A; Plebani M
    Int J Clin Lab Res; 1996; 26(1):33-6. PubMed ID: 8739853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN.
    Fabris P; Marranconi F; Bozzola L; Biasin MR; De Lazzari F; Plebani M; Benedetti P; Tositti G; Pellizzer G; Stecca C; de Lalla F
    J Gastroenterol; 1999 Jun; 34(3):345-50. PubMed ID: 10433010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.
    Yagura M; Murai S; Kojima H; Tokita H; Kamitsukasa H; Harada H
    J Gastroenterol; 2000; 35(2):105-11. PubMed ID: 10680665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term variations of serum laminin and procollagen III peptide in chronic HCV hepatitis after alpha-interferon therapy.
    Casaril M; Capra F; Gabrielli GB; Tognella P; Rizzi A; Squarzoni S; De Maria E; Colombari R; De Sandre G; Corrocher R
    Ital J Gastroenterol; 1996 Jan; 28(1):15-9. PubMed ID: 8743068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C.
    Mitsuda A; Suou T; Ikuta Y; Kawasaki H
    J Hepatol; 2000 Apr; 32(4):666-72. PubMed ID: 10782917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy.
    Sakaida I; Nagatomi A; Hironaka K; Uchida K; Okita K
    Am J Gastroenterol; 1999 Feb; 94(2):489-96. PubMed ID: 10022652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.
    Rao HY; Wei L; Li J; Zhang LF; Chen HY; Zhu LM; Liu F; Sun Y; Wang H
    Hepatogastroenterology; 2009; 56(90):328-34. PubMed ID: 19579592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha.
    Leroy V; De Traversay C; Barnoud R; Hartmann JD; Baud M; Ouzan D; Zarski JP
    J Hepatol; 2001 Jul; 35(1):120-6. PubMed ID: 11495029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative stress in chronic hepatitis C: the effect of interferon therapy and correlation with pathological features.
    Serejo F; Emerit I; Filipe PM; Fernandes AC; Costa MA; Freitas JP; de Moura MC
    Can J Gastroenterol; 2003 Nov; 17(11):644-50. PubMed ID: 14631465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis.
    Gabrielli GB; Capra F; Casaril M; Squarzoni S; Tognella P; Dagradi R; De Maria E; Colombari R; Corrocher R; De Sandre G
    Clin Chim Acta; 1997 Sep; 265(1):21-31. PubMed ID: 9352126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic alpha-smooth muscle actin expression in hepatitis C patients before and after interferon therapy.
    Khan MA; Poulos JE; Brunt EM; Li L; Solomon H; Britton RS; Bacon BR; Di Bisceglie AM
    Hepatogastroenterology; 2001; 48(37):212-5. PubMed ID: 11268968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa.
    Suou T; Hosho K; Kishimoto Y; Horie Y; Kawasaki H
    Hepatology; 1995 Aug; 22(2):426-31. PubMed ID: 7635409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease in serum levels of markers of hepatic connective tissue turnover during and after treatment of chronic hepatitis B with interferon-alpha.
    Teran JC; Mullen KD; Hoofnagle JH; McCullough AJ
    Hepatology; 1994 Apr; 19(4):849-56. PubMed ID: 8138256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum variations of 2 markers of fibrogenesis in chronic hepatitis C treated with alpha interferon].
    Soresi M; Bascone F; Agate V; Carroccio A; Barresi E; Cartabellotta A; Aragona F; Montalto G
    Recenti Prog Med; 1997 Feb; 88(2):73-6. PubMed ID: 9148370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
    Rao HY; Li J; Zhang LF; Chen HY; Zhu LM; Wei L; Sun Y; Wang H
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):96-100. PubMed ID: 18353212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of iron load on fibrogenesis in chronic hepatitis C.
    Casaril M; Stanzial AM; Tognella P; Pantalena M; Capra F; Colombari R; Corrocher R
    Hepatogastroenterology; 2000; 47(31):220-5. PubMed ID: 10690612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
    Tanwar S; Trembling PM; Hogan BJ; Srivastava A; Parkes J; Harris S; Grant P; Nastouli E; Ocker M; Wehr K; Herold C; Neureiter D; Schuppan D; Rosenberg WM
    Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):289-296. PubMed ID: 27906753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.